Aditxt's Subsidiary Pearsanta Advances Towards IPO to Fund Cancer Detection Innovations

Aditxt Inc. (NASDAQ: ADTX) has announced that its subsidiary, Pearsanta, Inc., is progressing with plans for an Initial Public Offering (IPO), with Spartan Capital Securities, LLC serving as the lead underwriter. This strategic move is aimed at securing the necessary funding for the clinical validation and commercial expansion of Pearsanta's groundbreaking early cancer and disease detection tests. These tests are based on the Mitomic mitochondrial DNA platform and are supported by a CLIA-certified, CAP-accredited laboratory infrastructure, ensuring high standards of accuracy and reliability.

Amro Albanna, CEO of Aditxt, emphasized the IPO's role in the company's broader Acquire, Build, and Capitalize strategy, which seeks to enhance market access for Pearsanta's diagnostic solutions. The importance of early detection in significantly improving patient outcomes cannot be overstated, and this initiative represents a pivotal advancement in the field of diagnostic technologies. Aditxt's commitment to accelerating health innovations is further demonstrated through its collaborative ecosystem, which brings together research institutions, industry partners, and shareholders to drive progress in health solutions.

Aditxt's innovative platform is designed to foster interdisciplinary collaboration, with current programs focusing on immune health and precision health. The company also has plans to expand its initiatives into public health and women's health, underscoring its dedication to addressing critical health challenges. The IPO of Pearsanta, Inc. is a testament to Aditxt's strategic approach to innovation and its impact on the future of healthcare diagnostics. For more information on Aditxt and its initiatives, visit https://www.aditxt.com.